Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates ...

Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to ...

Findings from an Italian cohort suggest that nusinersen may benefit fatigue measures in patients with spinal muscular atrophy (SMA) type III; however, drawing definitive conclusions in this area ...

Across the 18 patients with SMA1, nusinersen resulted in a significant reduction in CSF levels of some, though not all, of the neuroinflammatory molecules that were increased at baseline.

Treatment with nusinersen was linked to increased motor function and reduction of the neurodegenerative biomarker neurofilament light chain in children with spinal muscular atrophy, according to ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...